Daniel Ellis | Senior Scientist, Computational Discovery
Icosavax, Inc.

Daniel Ellis, Senior Scientist, Computational Discovery, Icosavax, Inc.

At Icosavax, Dan focuses on structure-based antigen design for multiple vaccine candidates. Prior to Icosavax, Dan completed his PhD at the Institute for Protein Design at the University of Washington, where he helped design and develop the two-component VLP technology used by Icosavax and further pursued design of vaccines for influenza and SARS-CoV-2.


Day 2 - November 29 @ 12:50

From computationally designed antigens to VLP-based antigen display – a recipe for best-in-class vaccines

last published: 02/Jan/24 12:15 GMT

back to speakers